UPLC-MS-MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome p450 activity study in rats

Journal of Chromatographic Science

Volumn 51, Issue 1, 2013, Pages 26-32

  Liu, Yan ^a   Li, Xiang ^a   Yang, Chunjuan ^a   Tai, Sheng ^a   Zhang, Xiangning ^a   Liu, Gaofeng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450; DAPSONE; METOPROLOL; TOLBUTAMIDE;

ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLISM; METHODOLOGY; RAT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; WISTAR RAT;

ANIMALS; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DAPSONE; DRUG STABILITY; LINEAR MODELS; MALE; METOPROLOL; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TOLBUTAMIDE;

RATTUS;

EID: 84871180119     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/bms100     Document Type: Article

References (23)

1. Wu, H., Yu, W., Huang, L., Wang, J., Tang, X., Yang, W., et al.; Effect of sodium ozagrel on the activity of rat CYP2D6; European Journal of Pharmacology, (2007); 573: 55-59. (Pubitemid 47464216)
2. Johnson, B.M., Song, I.H, Adkison, K.K., Borland, J., Fang, L., Lou, Y., et al.; Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 ± 1 cocktail; Journal of Clinical Pharmacology, (2006); 46: 577-587.
3. Spriet, I., Meersseman, W., de Hoon, J., von Winckelmann, S., Wilmer, A., Willems, L.; Mini-series: II. Clinical aspects Clinically relevant CYP450-mediated drug interactions in the ICU; Intensive Care Medicine, (2009); 35: 603-612.
4. Kennedy, D.A., Seely, D.; Clinically based evidence of drug-herb interactions: A systematic review; Expert Opinion on Drug Safety, (2010); 9: 79-124.
5. Zhang, X., Lalezari, J.P., Badley, A.D., Dorr, A., Kolis, S.J., Kinchelow, T., et al.; Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients; Clinical Pharmacology and Therapeutics, (2004); 75: 558-568. (Pubitemid 38746606)
6. Perera, V., Gross, A.S., McLachlan, A.J.; Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma; Biomedical Chromatography, (2010); 24: 1136- 1144.
7. Jerdi, M.C., Daali, Y., Oestreicher, M.K., Cherkaoui, S., Dayer, P.; A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes; Journal of Pharmaceutical and Biomedical Analysis, 35: (2004); 1203-1212. (Pubitemid 39140285)
8. Yao, Y.M., Cao, W., Cao, Y.J., Cheng, Z.N., Ou-Yang, D.S., Liu, Z.Q., et al.; Effect of sinomenine on human cytochrome P450 activity; Clinica Chimica Acta, (2007); 379: 113-118. (Pubitemid 46366978)
9. Cheng, J., Kong, W.J., Luo, Y., Wang, J.B., Wang, H.T., Li, Q.M., et al.; Development and validation of UPLC method for quality control of Curcuma longa Linn.: Fast simultaneous quantitation of three curcuminoids; Journal of Pharmaceutical and Biomedical Analysis, (2010); 53: 43-49.
10. Guillarme, D., Nguyen, D.T., Rudaz, S., Veuthey, J.L.; High throughout liquid chromatography with sub-2 microm particles at high pressure and high temperature; Journal of Chromatography A, (2007); 1149: 20-29.
11. Lee, G., White, S.A., Spooner, N.; Evaluation of ultra-performance liquid chromatography in the bioanalysis of small molecule drug candidates in plasma; Journal of Chromatographic Science, (2007); 45: 298-304. (Pubitemid 47025389)
12. Cao, W., Liu, W., Wu, T., Zhong, D., Liu, G.; Dengzhanhua preparations for acute cerebral infarction; Cochrane Database Systematic Reviews, (2008); CD005568.
13. Zhang, J., Li, X.S., Zhang, W.D.; Chemical constituents from herbs of Erigeron breviscapus and the progress of pharmacological study on it; Journal of Pharmaceutical Practice, (2002); 20: 103-107.
14. Chavez, M.L., Jordan, M.A., Chavez, P.I.; Evidence-based drug-herbal interactions; Life Sciences, (2006); 78: 2146-2157.
15. De Smet, P.A.; Clinical risk management of herb-drug interactions; British Journal of Pharmacology, (2007); 63: 258-267.
16. Izzo, A.A., Ernst, E.; Interactions between herbal medicines and prescribed drugs: An updated systematic review; Drugs, (2009); 69: 1777-1798.
17. Zhong, Y., Tang, J., Liao, P.; Observation of clinical effects of breviscapine combined with captopril on patients with chromic glomerulonephritis; Journal of Emergency in Traditional Chinese Medicine, (2008); 17: 784-785.
18. Peng, J.; Report of 52 cases about breviscapine and nimodipine in the treatment of diabetic polyneuropathy; Journal of Chinese Physician, (2004); 6: 130-113.
19. Mogili, R., Kanala, K., Challa, B.R., Chandu, B.R., Bannoth, C.K.; Development and validation of amisulpride in human plasma by HPLC coupled with tandem mass spectrometry and its application to a pharmacokinetic study; Scientia Pharmaceutia, (2011); 79: 583-599.
20. Xia, C.H., Sun, J.G., Wang, G.J., Shang, L.L., Zhang, X.X., Zhang, R., et al.; Herb-drug interactions: In vivo and in vitro effect of Shenmai Injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats; Planta Medica, (2010); 76: 245-250.
21. Hu, D.D., Gu, L., Yao, H.J., Liu, W., Wang, S.P., Liu, G.L.; Determination of four cytochrome P450 probe drugs by RP-HPLC in a single run; Chinese Pharmaceutical Journal, (2010); 45: 71-74.
22. Tang, H., Min, G.T., Ge, B., Li, Y.M., Liu, X., Jiang, S.X.; Evaluation of protective effects of Chi-Zhi-Huang decoction on Phase I drug metabolism of liver injured rats by cocktail probe drugs; Journal of Ethnopharmacology, (2008); 117: 420-426.
23. Bjornsson, T.D., Callaghan, J.T., Einolf, H.J., Fischer, V., Gan, L., Grimm, S., et al.; The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective; Drug Metabolism and Disposition, (2003); 31: 815-832. (Pubitemid 36759050)